Stock News

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
aTyr Pharma to Present at the Jefferies London Healthcare Conference
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Life Sciences Virtual Investor Conference Agenda Announced for September 15th

As seen on...